Superior semaglutide
Novo Nordisk has published positive results from the SUSTAIN 7 trial showing that Semaglutide is superior to dulaglutide (Eli Lilly) in both glucose control and weight loss in people with type 2 diabetes. We view superiority as a very strong selling point and reiterate that patients/doctors have few good arguments for choosing Trulisity once semaglutide is available. We maintain our HOLD recommendation but have raised our target price to DKK310 (300) based on the strong SUSTAIN 7 data.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.